Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ryeqo on Hemostasis Parameters in Uterine Fibroids and Endometriosis
NCT07173127Recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of relugolix + estradiol + norethindrone in Uterine Fibroids (UF) and endometriosis. Primary endpoint: Normalized activated protein C resistance at 3 months. Started Sep 2025; status: recruiting.
02
Drugs
relugolix + estradiol + norethindrone
03
Conditions
Uterine Fibroids (UF)endometriosis
Beyond the preview
Go deeper on NCT07173127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07173127.